Evaluation  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
hematocrit  ||| S:14 E:25 ||| JJ
interference  ||| S:25 E:38 ||| NN
with  ||| S:38 E:43 ||| IN
MyStar  ||| S:43 E:50 ||| JJ
extra  ||| S:50 E:56 ||| JJ
and  ||| S:56 E:60 ||| CC
seven  ||| S:60 E:66 ||| CD
competitive  ||| S:66 E:78 ||| JJ
devices  ||| S:78 E:86 ||| NNS
In  ||| S:86 E:89 ||| IN
previous  ||| S:89 E:98 ||| JJ
studies ||| S:98 E:105 ||| NNS
,  ||| S:105 E:107 ||| ,
meters  ||| S:107 E:114 ||| FW
employing  ||| S:114 E:124 ||| FW
dynamic  ||| S:124 E:132 ||| FW
electrochemistry  ||| S:132 E:149 ||| FW
( ||| S:149 E:150 ||| -LRB-
DE ||| S:150 E:152 ||| NNP
) ||| S:152 E:153 ||| -RRB-
,  ||| S:153 E:155 ||| ,
have  ||| S:155 E:160 ||| VBP
been  ||| S:160 E:165 ||| VBN
shown  ||| S:165 E:171 ||| VBN
to  ||| S:171 E:174 ||| TO
correct  ||| S:174 E:182 ||| VB
for  ||| S:182 E:186 ||| IN
hematocrit  ||| S:186 E:197 ||| NNS
( ||| S:197 E:198 ||| -LRB-
HCT ||| S:198 E:201 ||| NNP
)  ||| S:201 E:203 ||| -RRB-
interference ||| S:203 E:215 ||| NN
.  ||| S:215 E:217 ||| .
This  ||| S:217 E:222 ||| DT
laboratory  ||| S:222 E:233 ||| NN
investigation  ||| S:233 E:247 ||| NN
assessed  ||| S:247 E:256 ||| VBD
the  ||| S:256 E:260 ||| DT
HCT  ||| S:260 E:264 ||| NNP
stability  ||| S:264 E:274 ||| NN
of  ||| S:274 E:277 ||| IN
MyStar  ||| S:277 E:284 ||| NNP
Extra  ||| S:284 E:290 ||| NNP
( ||| S:290 E:291 ||| -LRB-
Sanofi ||| S:291 E:297 ||| NNP
)  ||| S:297 E:299 ||| -RRB-
in  ||| S:299 E:302 ||| IN
comparison  ||| S:302 E:313 ||| NN
to  ||| S:313 E:316 ||| TO
7  ||| S:316 E:318 ||| CD
competitive  ||| S:318 E:330 ||| JJ
devices  ||| S:330 E:338 ||| NNS
( ||| S:338 E:339 ||| -LRB-
Accu-Chek  ||| S:339 E:349 ||| NNP
Aviva  ||| S:349 E:355 ||| NNP
Nano  ||| S:355 E:401 ||| NNP
Contour  ||| S:401 E:409 ||| NNP
XT  ||| S:409 E:412 ||| NNP
and  ||| S:412 E:416 ||| CC
Contour  ||| S:416 E:424 ||| NNP
Link ||| S:424 E:428 ||| NNP
,  ||| S:428 E:430 ||| ,
Bayer ||| S:430 E:435 ||| NNP
;  ||| S:435 E:437 ||| :
FreeStyle  ||| S:437 E:447 ||| NNP
Freedom  ||| S:447 E:455 ||| NNP
Lite ||| S:455 E:459 ||| NNP
,  ||| S:459 E:461 ||| ,
Abbott ||| S:461 E:467 ||| NNP
;  ||| S:467 E:469 ||| :
MyLife  ||| S:469 E:476 ||| NNP
Pura ||| S:476 E:480 ||| NNP
,  ||| S:480 E:482 ||| ,
Ypsomed ||| S:482 E:489 ||| NNP
;  ||| S:489 E:491 ||| :
OneTouch  ||| S:491 E:500 ||| NNP
Verio  ||| S:500 E:506 ||| NNP
Pro ||| S:506 E:509 ||| NNP
,  ||| S:509 E:511 ||| ,
LifeScan ||| S:511 E:519 ||| NNP
) ||| S:519 E:520 ||| -RRB-
.  ||| S:520 E:522 ||| .
Venous  ||| S:522 E:529 ||| JJ
heparinized  ||| S:529 E:541 ||| JJ
blood  ||| S:541 E:547 ||| NN
was  ||| S:547 E:551 ||| VBD
freshly  ||| S:551 E:559 ||| RB
drawn ||| S:559 E:564 ||| VBN
,  ||| S:564 E:566 ||| ,
immediately  ||| S:566 E:578 ||| RB
aliquoted ||| S:578 E:587 ||| JJ
,  ||| S:587 E:589 ||| ,
and  ||| S:589 E:593 ||| CC
manipulated  ||| S:593 E:605 ||| VBN
to  ||| S:605 E:608 ||| TO
contain  ||| S:608 E:616 ||| VB
3  ||| S:616 E:618 ||| CD
different  ||| S:618 E:628 ||| JJ
blood  ||| S:628 E:634 ||| NN
glucose  ||| S:634 E:642 ||| NN
concentrations  ||| S:642 E:657 ||| NNS
( ||| S:657 E:658 ||| -LRB-
50-80  ||| S:658 E:664 ||| FW
mg ||| S:664 E:666 ||| FW
/ ||| S:666 E:667 ||| FW
dL ||| S:667 E:669 ||| FW
,  ||| S:669 E:671 ||| ,
150-180  ||| S:671 E:679 ||| FW
mg ||| S:679 E:681 ||| FW
/ ||| S:681 E:682 ||| FW
dL ||| S:682 E:684 ||| FW
,  ||| S:684 E:686 ||| ,
and  ||| S:686 E:690 ||| CC
350-400  ||| S:690 E:698 ||| FW
mg ||| S:698 E:700 ||| FW
/ ||| S:700 E:701 ||| FW
dL ||| S:701 E:703 ||| FW
)  ||| S:703 E:705 ||| -RRB-
and  ||| S:705 E:709 ||| CC
5  ||| S:709 E:711 ||| CD
different  ||| S:711 E:721 ||| JJ
HCT  ||| S:721 E:725 ||| NN
levels  ||| S:725 E:732 ||| NNS
( ||| S:732 E:733 ||| -LRB-
20-25 ||| S:733 E:738 ||| NNP
% ||| S:738 E:739 ||| NN
,  ||| S:739 E:741 ||| ,
30-35 ||| S:741 E:746 ||| CD
% ||| S:746 E:747 ||| NN
,  ||| S:747 E:749 ||| ,
40-45 ||| S:749 E:754 ||| CD
% ||| S:754 E:755 ||| NN
,  ||| S:755 E:757 ||| ,
50-55 ||| S:757 E:762 ||| CD
% ||| S:762 E:763 ||| NN
,  ||| S:763 E:765 ||| ,
and  ||| S:765 E:769 ||| CC
60-65 ||| S:769 E:774 ||| CD
% ||| S:774 E:775 ||| NN
) ||| S:775 E:776 ||| -RRB-
.  ||| S:776 E:778 ||| .
After  ||| S:778 E:784 ||| IN
careful  ||| S:784 E:792 ||| JJ
oxygenation  ||| S:792 E:804 ||| NN
to  ||| S:804 E:807 ||| TO
normal  ||| S:807 E:814 ||| JJ
blood  ||| S:814 E:820 ||| NN
oxygen  ||| S:820 E:827 ||| NN
pressure ||| S:827 E:835 ||| NN
,  ||| S:835 E:837 ||| ,
each  ||| S:837 E:842 ||| DT
of  ||| S:842 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
15  ||| S:849 E:852 ||| CD
different  ||| S:852 E:862 ||| JJ
samples  ||| S:862 E:870 ||| NNS
was  ||| S:870 E:874 ||| VBD
measured  ||| S:874 E:883 ||| VBN
8  ||| S:883 E:885 ||| CD
times  ||| S:885 E:891 ||| NNS
with  ||| S:891 E:896 ||| IN
2  ||| S:896 E:898 ||| CD
devices  ||| S:898 E:906 ||| NNS
and  ||| S:906 E:910 ||| CC
2  ||| S:910 E:912 ||| CD
strip  ||| S:912 E:918 ||| NN
lots  ||| S:918 E:923 ||| NNS
of  ||| S:923 E:926 ||| IN
each  ||| S:926 E:931 ||| DT
meter  ||| S:931 E:937 ||| NN
( ||| S:937 E:938 ||| -LRB-
32  ||| S:938 E:941 ||| CD
measurements ||| S:941 E:953 ||| CD
/ ||| S:953 E:954 ||| CD
meter ||| S:954 E:959 ||| CD
/ ||| S:959 E:960 ||| CD
sample ||| S:960 E:966 ||| NN
) ||| S:966 E:967 ||| -RRB-
.  ||| S:967 E:969 ||| .
YSI  ||| S:969 E:973 ||| NNP
Stat  ||| S:973 E:978 ||| NNP
2300  ||| S:978 E:983 ||| CD
served  ||| S:983 E:990 ||| VBN
as  ||| S:990 E:993 ||| IN
laboratory  ||| S:993 E:1004 ||| NN
reference  ||| S:1004 E:1014 ||| NN
method ||| S:1014 E:1020 ||| NN
.  ||| S:1020 E:1022 ||| .
Next  ||| S:1022 E:1027 ||| JJ
to  ||| S:1027 E:1030 ||| TO
determination  ||| S:1030 E:1044 ||| NN
of  ||| S:1044 E:1047 ||| IN
the  ||| S:1047 E:1051 ||| DT
mean  ||| S:1051 E:1056 ||| JJ
absolute  ||| S:1056 E:1065 ||| JJ
relative  ||| S:1065 E:1074 ||| JJ
deviation  ||| S:1074 E:1084 ||| NN
( ||| S:1084 E:1085 ||| -LRB-
MARD ||| S:1085 E:1089 ||| NNP
) ||| S:1089 E:1090 ||| -RRB-
,  ||| S:1090 E:1092 ||| ,
stability  ||| S:1092 E:1102 ||| NN
to  ||| S:1102 E:1105 ||| TO
HCT  ||| S:1105 E:1109 ||| NNP
influence  ||| S:1109 E:1119 ||| NN
was  ||| S:1119 E:1123 ||| VBD
assumed ||| S:1123 E:1130 ||| VBN
,  ||| S:1130 E:1132 ||| ,
when  ||| S:1132 E:1137 ||| WRB
less  ||| S:1137 E:1142 ||| JJR
than  ||| S:1142 E:1147 ||| IN
10 ||| S:1147 E:1149 ||| CD
%  ||| S:1149 E:1151 ||| NN
difference  ||| S:1151 E:1162 ||| NN
occurred  ||| S:1162 E:1171 ||| VBD
between  ||| S:1171 E:1179 ||| IN
the  ||| S:1179 E:1183 ||| DT
highest  ||| S:1183 E:1191 ||| JJS
and  ||| S:1191 E:1195 ||| CC
lowest  ||| S:1195 E:1202 ||| JJS
mean  ||| S:1202 E:1207 ||| VBP
glucose  ||| S:1207 E:1215 ||| JJ
deviations  ||| S:1215 E:1226 ||| NNS
in  ||| S:1226 E:1229 ||| IN
relation  ||| S:1229 E:1238 ||| NN
to  ||| S:1238 E:1241 ||| TO
HCT  ||| S:1241 E:1245 ||| NNP
over  ||| S:1245 E:1250 ||| IN
all  ||| S:1250 E:1254 ||| DT
tested  ||| S:1254 E:1261 ||| JJ
glucose  ||| S:1261 E:1269 ||| NN
ranges  ||| S:1269 E:1276 ||| NNS
( ||| S:1276 E:1277 ||| -LRB-
HIF ||| S:1277 E:1280 ||| NNP
:  ||| S:1280 E:1282 ||| :
hematocrit  ||| S:1282 E:1293 ||| JJ
interference  ||| S:1293 E:1306 ||| NN
factor ||| S:1306 E:1312 ||| NN
) ||| S:1312 E:1313 ||| -RRB-
.  ||| S:1313 E:1315 ||| .
Four  ||| S:1315 E:1320 ||| CD
of  ||| S:1320 E:1323 ||| IN
the  ||| S:1323 E:1327 ||| DT
devices  ||| S:1327 E:1335 ||| NNS
showed  ||| S:1335 E:1342 ||| VBD
stable  ||| S:1342 E:1349 ||| JJ
performance ||| S:1349 E:1360 ||| NN
:  ||| S:1360 E:1362 ||| :
Contour  ||| S:1362 E:1370 ||| NNP
XT  ||| S:1370 E:1373 ||| NNP
( ||| S:1373 E:1374 ||| -LRB-
MARD ||| S:1374 E:1378 ||| NNP
:  ||| S:1378 E:1380 ||| :
1.3 ||| S:1380 E:1383 ||| CD
% ||| S:1383 E:1384 ||| NN
/ ||| S:1384 E:1385 ||| NNP
HIF ||| S:1385 E:1388 ||| NNP
:  ||| S:1388 E:1390 ||| :
6.1 ||| S:1390 E:1393 ||| CD
% ||| S:1393 E:1394 ||| NN
) ||| S:1394 E:1395 ||| -RRB-
,  ||| S:1395 E:1397 ||| ,
MyStar  ||| S:1397 E:1404 ||| NNP
Extra  ||| S:1404 E:1410 ||| NNP
( ||| S:1410 E:1411 ||| -LRB-
4.7 ||| S:1411 E:1414 ||| CD
% ||| S:1414 E:1415 ||| NN
/ ||| S:1415 E:1416 ||| CD
7.1 ||| S:1416 E:1419 ||| CD
% ||| S:1419 E:1420 ||| NN
) ||| S:1420 E:1421 ||| -RRB-
,  ||| S:1421 E:1423 ||| ,
OneTouch  ||| S:1423 E:1432 ||| FW
Verio  ||| S:1432 E:1438 ||| FW
Pro  ||| S:1438 E:1442 ||| FW
( ||| S:1442 E:1443 ||| -LRB-
4.5 ||| S:1443 E:1446 ||| CD
% ||| S:1446 E:1447 ||| NN
/ ||| S:1447 E:1448 ||| CD
7.3 ||| S:1448 E:1451 ||| CD
% ||| S:1451 E:1452 ||| NN
) ||| S:1452 E:1453 ||| -RRB-
,  ||| S:1453 E:1455 ||| ,
and  ||| S:1455 E:1459 ||| CC
Contour  ||| S:1459 E:1467 ||| NNP
Link  ||| S:1467 E:1472 ||| NNP
( ||| S:1472 E:1473 ||| -LRB-
6.3 ||| S:1473 E:1476 ||| CD
% ||| S:1476 E:1477 ||| NN
/ ||| S:1477 E:1478 ||| CD
9.3 ||| S:1478 E:1481 ||| CD
% ||| S:1481 E:1482 ||| NN
) ||| S:1482 E:1483 ||| -RRB-
.  ||| S:1483 E:1485 ||| .
The  ||| S:1485 E:1489 ||| DT
4  ||| S:1489 E:1491 ||| CD
other  ||| S:1491 E:1497 ||| JJ
meters  ||| S:1497 E:1504 ||| NNS
were  ||| S:1504 E:1509 ||| VBD
influenced  ||| S:1509 E:1520 ||| VBN
by  ||| S:1520 E:1523 ||| IN
HCT  ||| S:1523 E:1527 ||| NNP
( ||| S:1527 E:1528 ||| -LRB-
Accu-Chek  ||| S:1528 E:1538 ||| NNP
Performa ||| S:1538 E:1546 ||| NNP
:  ||| S:1546 E:1548 ||| :
4.7 ||| S:1548 E:1551 ||| CD
% ||| S:1551 E:1552 ||| NN
/ ||| S:1552 E:1553 ||| CD
20.9 ||| S:1553 E:1557 ||| CD
% ||| S:1557 E:1558 ||| NN
,  ||| S:1558 E:1560 ||| ,
Accu-Chek  ||| S:1560 E:1570 ||| NNP
Aviva  ||| S:1570 E:1576 ||| NNP
Nano ||| S:1576 E:1580 ||| NNP
:  ||| S:1580 E:1582 ||| :
4.5 ||| S:1582 E:1585 ||| CD
% ||| S:1585 E:1586 ||| NN
/ ||| S:1586 E:1587 ||| CD
22.4 ||| S:1587 E:1591 ||| CD
% ||| S:1591 E:1592 ||| NN
,  ||| S:1592 E:1594 ||| ,
FreeStyle  ||| S:1594 E:1604 ||| NNP
Freedom  ||| S:1604 E:1612 ||| NNP
Lite ||| S:1612 E:1616 ||| NNP
:  ||| S:1616 E:1618 ||| :
4.8 ||| S:1618 E:1621 ||| CD
% ||| S:1621 E:1622 ||| NN
/ ||| S:1622 E:1623 ||| CD
24.5 ||| S:1623 E:1627 ||| CD
% ||| S:1627 E:1628 ||| NN
;  ||| S:1628 E:1630 ||| :
MyLife  ||| S:1630 E:1637 ||| NNP
Pura ||| S:1637 E:1641 ||| NNP
:  ||| S:1641 E:1643 ||| :
6.4 ||| S:1643 E:1646 ||| CD
% ||| S:1646 E:1647 ||| NN
/ ||| S:1647 E:1648 ||| CD
28.7 ||| S:1648 E:1652 ||| CD
% ||| S:1652 E:1653 ||| NN
) ||| S:1653 E:1654 ||| -RRB-
.  ||| S:1654 E:1656 ||| .
In  ||| S:1656 E:1659 ||| IN
this  ||| S:1659 E:1664 ||| DT
study ||| S:1664 E:1669 ||| NN
,  ||| S:1669 E:1671 ||| ,
all  ||| S:1671 E:1675 ||| DT
meters  ||| S:1675 E:1682 ||| NNS
showed  ||| S:1682 E:1689 ||| VBD
a  ||| S:1689 E:1691 ||| DT
good  ||| S:1691 E:1696 ||| JJ
accuracy ||| S:1696 E:1704 ||| NN
,  ||| S:1704 E:1706 ||| ,
but  ||| S:1706 E:1710 ||| CC
only  ||| S:1710 E:1715 ||| RB
50 ||| S:1715 E:1717 ||| CD
%  ||| S:1717 E:1719 ||| NN
of  ||| S:1719 E:1722 ||| IN
them ||| S:1722 E:1726 ||| PRP
,  ||| S:1726 E:1728 ||| ,
including  ||| S:1728 E:1738 ||| VBG
MyStar  ||| S:1738 E:1745 ||| JJ
Extra ||| S:1745 E:1750 ||| NNP
,  ||| S:1750 E:1752 ||| ,
were  ||| S:1752 E:1757 ||| VBD
shown  ||| S:1757 E:1763 ||| VBN
to  ||| S:1763 E:1766 ||| TO
reliably  ||| S:1766 E:1775 ||| VB
correct  ||| S:1775 E:1783 ||| JJ
for  ||| S:1783 E:1787 ||| IN
potential  ||| S:1787 E:1797 ||| JJ
hematocrit  ||| S:1797 E:1808 ||| JJ
influence  ||| S:1808 E:1818 ||| NN
on  ||| S:1818 E:1821 ||| IN
the  ||| S:1821 E:1825 ||| DT
meter  ||| S:1825 E:1831 ||| JJ
results ||| S:1831 E:1838 ||| NNS
.  ||| S:1838 E:1840 ||| .
